List view / Grid view

VELCADE® (bortezomib)



European Commission approves additional indication for VELCADE® (bortezomib) in mantle cell lymphoma

6 February 2015 | By Janssen EMEA

Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved a variation to the terms of the marketing authorisation of VELCADE® (bortezomib) in combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are unsuitable for blood…